Efficacy, Safety of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy Among Patients With Extensive-Stage Small-Cell Lung Cancer
According to results from a phase 2 study, adebrelimab plus chemotherapy and sequential thoracic radiotherapy demonstrated promising clinical efficacy and safety in the first-line setting among patients with extensive-stage small-cell lung cancer (SCLC).
These data were presented by Dawei Chen, MD, PhD, Shandong Cancer Hospital and Institute, Jinan, China, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
In this study, 67 patients received 4 to 6 cycles of 200 mg/kg adebrelimab plus chemotherapy (either etoposide plus cisplatin or carboplatin) once every 3 weeks. Patients with response sequentially received adebrelimab and consolidative thoracic radiotherapy (≥30 Gy in 10 fractions or ≥50 Gy in 25 fractions). Treatment was followed by maintenance adebrelimab until disease progression or unacceptable toxicity. The primary end point was overall survival (OS). Key secondary end points included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and safety.
At the data cutoff point, median follow-up duration was 17.7 months. Median OS was 21.4 months with a 1-year OS rate of 74% and a 2-year OS rate of 39.7%. Median PFS was 10.1 months. The confirmed ORR was 71.6%, and DCR was 89.6%. The most common grade ≥3 treatment-related adverse events included neutrophil count decrease (41.8%), white blood cell count decrease (19.4%), and lymphocyte count decrease (13.4%).
“Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small cell lung cancer showed promising efficacy and acceptable safety,” concluded Dr Chen. “The results warrant for the clinical studies of chemoimmunotherapy combined with thoracic radiotherapy in extensive-stage small cell lung cancer.”
Source:
Chen D, Gao A, Zou B, et al. Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. Presented at the ASCO Annual Meeting. May 31-June 4, 2024; Chicago, IL. Abstract #8014
